Black Rock Inc. Synaptogenix, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.16 - $0.3 $33 - $63	-210 Reduced 22.29%	732 $0
Q4 2023 Feb 13, 2024	BUY	$0.23 - $0.4 $48 - $84	210 Added 28.69%	942 $0
Q3 2023 Nov 13, 2023	SELL	$0.28 - $1.04 $648 - $2,407	-2,315 Reduced 75.98%	732 $0
Q2 2023 Aug 11, 2023	SELL	$0.78 - $1.0 $10,813 - $13,864	-13,864 Reduced 81.98%	3,047 $2,000
Q1 2023 May 12, 2023	BUY	$0.8 - $1.33 $417 - $694	522 Added 3.19%	16,911 $13,000
Q4 2022 Feb 13, 2023	BUY	$1.02 - $181.75 $354 - $63,249	348 Added 2.17%	16,389 $19,000
Q3 2022 Nov 14, 2022	BUY	$4.6 - $172.25 $1,366 - $51,158	297 Added 1.89%	16,041 $108,000
Q2 2022 Aug 12, 2022	BUY	$3.88 - $7.41 $61,086 - $116,663	15,744 New	15,744 $81,000

30K

Ticker SNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,840,630
Market Cap $22.9M
Description
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.